ObjectiveTo explore the potential mechanism of Weicanqing Formula （微残清方， WF） combined with chemotherapy in treating acute myeloid leukemia （AML） based on malic enzyme 2 （ME2）-mediated bone marrow immune-metabolic homeostasis and . MethodsSixty-five male C57BL/6N mice were randomly divided into control group， model group， WF group， chemotherapy group， and the combination group （WF plus chemotherapy）， with 13 mice per group. Except for the control group， mice were injected with C1498 cells （appro-ximately 1×10⁶ cells per mouse） via the tail vein on day 1 to establish an AML model. Starting from day 8， mice in the chemotherapy group and the combination group were administered with cytarabine at 30 mg/（kg·d） via subcutaneous injection， once daily for 3 consecutive days； WF group and the combination group received WF at 7.54 g/（kg·d） by gavage， once daily for 21 consecutive days. On days 1， 7， 14， 21 and 28， hemoglobin （Hb） and white blood cell （WBC） levels were determined in each group. On day 28， Giemsa staining was used to observe morphological changes in bone marrow cells. Flow cytometry was employed to detect the expression levels of bone marrow T lympthocyte subsets， including CD8⁺， CD4⁺， and regulatory T lymphocytes （Treg）. The contents of glutamine （Gln）， nicotinamide adenine dinucleotide phosphate （NADP⁺）， and reduced nicotinamide adenine dinucleotide phosphate （NADPH） in bone marrow were determined using visible spectrophotometry. Adenosine triphosphate （ATP） concentration in bone marrow was measured by chemiluminescence assay. The mRNA expression of malic enzyme 2 （ME2） in bone marrow was detected by RT-qPCR， and the protein expression level of ME2 was determined by Western blotting. ResultsCompared to the control group， the model group showed decreased Hb levels on day 14， 21， and 28， and increased WBC levels on day 7， 14， 21， and 28 （P＜0.05）. On day 28， bone marrow CD8⁺ and CD8⁺/CD4⁺ levels decreased， while Treg cells， ATP， Gln， NADP⁺， NADPH， ME2 mRNA， and their corresponding protein levels increased （P＜0.05）. Compared to the model group， the chemotherapy group and the combination group both exhibited reduced Hb level on day 14， 21 and 28， as well as the increased WBC level； the combination group showed increased CD8⁺ level， decreased Treg， ATP， Gln， and NADPH content， as well as reduced ME2 mRNA expression and protein levels （P＜0.05）. Compared to the chemotherapy group， the combination group showed significantly increased Hb level on days 21 and 28， and increased WBC level on day 28 （P＜0.05）. Bone marrow smear pathology revealed that， in the model group， myeloid blast cells exhibited cytoplasmic vacuoles indicative of abnormal metabolic activity. In contrast， both the chemotherapy group and the combination group showed large numbers of metamyelocytes and band neutrophils， with only a few immature granulocytic blast cells observed. ConclusionWF may improve the prognosis of AML when used as an adjunct to chemotherapy by modulating ME2 expression， inhibiting metabolic energy competition within the bone marrow microenvironment， and reshaping the distribution of T lymphocyte subsets in the bone marrow.

This study summarizes the characteristics and issues of the available undergraduate course of "Patient Safety" in terms of the teaching model, methods, and evaluation. Based on the theories of learning transfer and conceive-design-implement-operate, this study proposes a framework for course teaching reform of "Patient Safety" through a digital intelligence-empowered project-based teaching method. Moreover, teaching reform measures in the following three aspects are implemented, including the reform of teaching model through digital intelligence-empowered projects, the reform of teaching content, methods, and means by incorporating digital intelligence technology, and the reform of learning outcome evaluation by combining process and outcome assessments. Additionally, the study preliminarily explores the conditions for implementing the new teaching reforms and their effectiveness, providing a reference for the construction of similar courses.

Objective To explore the application efficacy of refined management on antimicrobial agents in a chest specialty hospital.Methods Multiple measures were implemented through perfecting management systems and processes,as well as conducting knowledge training,such as multi-dimensional specialized prescription reviewing,optimizing information systems,and implementing grid-based management of clinical pharmacist.A refined manage-ment mode for antimicrobial agents in a chest specialty hospital has been established.Antimicrobial management in-dicators for the whole hospital and each clinical specialty in 2023(before management)and 2024(after manage-ment)were analyzed.Results Compared with 2023,antimicrobial use rate among hospitalized patients in 2024 de-creased from 47.48％to 45.92％,and antimicrobial use density(AUD)decreased from 46.28 defined daily doses(DDDs)/(100 person·day)to 39.73 DDDs/(100 person·day).The ratio of antimicrobial cost to total drug cost decreased from 12.71％to 9.51％,and the per capita cost of antimicrobial use decreased from 1 344.18 Yuan to 975.52 Yuan.The use rate of prophylactic antimicrobial agents for class Ⅰ incision surgery increased from 84.48％to 89.52％,and the rationality rate increased from 69.25％to 94.53％.The management indicators of each clinical specialty improved significantly.Conclusion Through adopting a series of refined management measures,antimi-crobial management modes that are suitable for the actual situation of the hospital has been constructed,and obvious efficacy was achieved.Clinical application of antimicrobial agents is more standardized and rational.

Objective:To explore the clinicopathological characteristics and prognostic factors of hormone receptor-positive/human epidermal growth factor receptor 2-positive (HR +/HER2 +) breast cancer, and to construct a nomogram model for predicting the prognosis of patients. Methods:SEER*Stat 8.3.5 software was used to screen out the data of 11 664 HR +/HER2 + and 5,054 HR -/HER2 + breast cancer patients from 2010 to 2015 from the Surveillance, Epidemiology, and End Results (SEER) database. The clinicopathological data of the both groups were compared and the overall survival of the both groups was analyzed by using the Kaplan-Meier method and log-rank test was also performed; the factors influencing the overall survival in HR +/HER2 + patients with breast cancer were analyzed by using the Cox proportional hazards model. According to multivariate Cox regression analysis results, the median of the probability values of combined variables (linear predictive values) was calculated by using MedCalc software, with ≥ the median classified as high-risk group and < the median as low-risk group; the risk factor affinity diagrams were constructed by using R4.0.3 software. Based on the independent influencing factors of the overall survival in HR +/HER2 + breast cancer patients, a nomogram model to predict the 1-, 3-, 5-year overall survival of patients was established; the receiver operating characteristic (ROC) curve and calibration curve were plotted, and the predictive efficacy of the model was verified. Results:The differences in the proportions of HR +/HER2 + and HR -/HER2 + breast cancer patients with different age, race, histological grade, surgical method, whether receiving radiotherapy or chemotherapy, T stage, N stage, and M stage were statistically significant (all P < 0.05). The overall survival of HR +/HER2 + patients was better than that of HR -/HER2 + patients ( P < 0.001). Cox regression analysis showed that age, race, histological grade, surgical method, whether receiving radiotherapy or chemotherapy, first primary tumor or not, T stage, N stage, and M stage were independent influencing factors of overall survival in HR +/HER2 + patients (all P < 0.05). MedCalc software was used to obtain the median of the linear predictive values (0.394), with ≥ 0.394 classified as the high-risk group (5 838 cases) and < 0.394 as the low-risk group (5 826 cases). The risk factor affinity diagrams showed that all risk factors were more highly expressed in high-risk group compared with those in low-risk group; the overall survival of patients in high-risk group was poorer than that in low-risk group ( P < 0.001). The area under the ROC curve of a nomogram model for predicting the 1-, 3-, and 5-year overall survival rates was 0.900, 0.760, 0.760, respectively; and C index was 0.799, and the calibration curve was highly matched with the ideal curve. Conclusions:The prognosis of HR +/HER2 + patients is better than that of HR -/HER2 + patients. The constructed risk factor affinity diagrams and nomograms can well predict the prognosis of HR +/HER2 + breast cancer patients, which have a high clinical reference value.

Objective:To investigate the efficacy and safety of trastuzumab deruxtecan (T-DXd) in the treatment of metastatic breast cancer.Methods:A retrospective case series study was conducted. The clinical data of 38 breast cancer patients with metastasis in other parts who received T-DXd treatment in Xi'an International Medical Center Hospital from August 2021 to August 2024 were analyzed. The clinical efficacy and incidence of adverse reactions in patients were recorded, comparison of clinical efficacy in stratified patients based on clinical characteristics was performed, and the progression-free survival (PFS) was analyzed using Kaplan-Meier method.Results:All 38 patients were female, with a median age [ M ( Q1, Q3)] of 55 (42, 60) years; according to the guidelines of the American Society of Clinical Oncology/College of American Pathologists, 13 cases (34.2%) were positive for human epidermal growth factor receptor 2 (HER2) and 25 cases (65.8%) were low in HER2 expression; the Eastern Cooperative Oncology Group (ECOG) physical status scores of 23 cases (60.5%) were 0-2 points and 15 cases (39.5%) were 3-4 points; the median number of T-DXd treatment lines was 4 (2,16) lines. According to the Response Evaluation Criteria in Solid Tumors 1.1, the objective response rate (ORR) of T-DXd treatment was 34.2% (13/38), and the disease control rate (DCR) was 78.9% (30/38); the ORR of patients aged ≤ 50 years old was higher than that of patients aged >50 years old [56.3% (9/16) vs. 18.2% (4/22)], patients with HER2 positive was lower than that of patients with low HER2 expression [100.0 (13/13) vs. 68.0% (17/25)], patients with previous tyrosine kinase inhibitor (TKI) treatment was higher than that of patients without TKI treatment [100.0% (12/12) vs. 69.2% (18/26)], and the DCR of patients with T-DXd treatment for ≥ 4 cycles was higher than that of patients with T-DXd treatment for 1-3 cycles [100.0% (25/25) vs. 38.5% (5/13)], and the differences were statistically significant (all P < 0.05). Among the 38 patients, 19 (50.0%) stopped medication due to disease progression, 11 (28.9%) stopped medication due to economic reasons, 1 (0.8%) stopped medication due to grade 3 nausea and vomiting, and 1 (0.8%) stopped medication due to grade 2 interstitial lung disease (ILD), while the remaining 6 (15.8%) were undergoing T-DXd treatment. The median follow-up time was 9.5 (3.9, 17.8) months, and 16 cases (42.1%) progressed and died; the median PFS time was 5.9 months (95% CI: 3.1-8.7 months). Adverse reactions were mostly grade 1-2; common hematological adverse reactions included leukopenia [18 cases (47.3%)], neutropenia [16 cases (42.1%)], thrombocytopenia [11 cases (28.9%)], and anemia [15 cases (39.5%)]. Non-hematological adverse reactions included nausea [28 cases (73.7%)], vomiting [15 cases (39.5%)], decreased appetite [20 cases (52.6%)], fatigue [22 cases (57.9%)], alopecia [22 cases (57.5%)], elevated aspartate aminotransferase [20 cases (52.6%)], and elevated alanine aminotransferase [15 cases (39.5%)] were more common. Two cases developed interstitial lung disease (ILD), classified as grade 1 and grade 2, respectively. After discontinuation of medication and treatment with methylprednisolone, they returned to normal. Conclusions:T-DXd ≥ 2 line therapy has good efficacy and safety in the treatment of HER2 positive or low expression metastatic breast cancer. Bone marrow suppression and gastrointestinal adverse reactions are the most common, and the occurrence of ILD should be noted in the treatment.

Objective To explore the application efficacy of refined management on antimicrobial agents in a chest specialty hospital.Methods Multiple measures were implemented through perfecting management systems and processes,as well as conducting knowledge training,such as multi-dimensional specialized prescription reviewing,optimizing information systems,and implementing grid-based management of clinical pharmacist.A refined manage-ment mode for antimicrobial agents in a chest specialty hospital has been established.Antimicrobial management in-dicators for the whole hospital and each clinical specialty in 2023(before management)and 2024(after manage-ment)were analyzed.Results Compared with 2023,antimicrobial use rate among hospitalized patients in 2024 de-creased from 47.48％to 45.92％,and antimicrobial use density(AUD)decreased from 46.28 defined daily doses(DDDs)/(100 person·day)to 39.73 DDDs/(100 person·day).The ratio of antimicrobial cost to total drug cost decreased from 12.71％to 9.51％,and the per capita cost of antimicrobial use decreased from 1 344.18 Yuan to 975.52 Yuan.The use rate of prophylactic antimicrobial agents for class Ⅰ incision surgery increased from 84.48％to 89.52％,and the rationality rate increased from 69.25％to 94.53％.The management indicators of each clinical specialty improved significantly.Conclusion Through adopting a series of refined management measures,antimi-crobial management modes that are suitable for the actual situation of the hospital has been constructed,and obvious efficacy was achieved.Clinical application of antimicrobial agents is more standardized and rational.

This study summarizes the characteristics and issues of the available undergraduate course of "Patient Safety" in terms of the teaching model, methods, and evaluation. Based on the theories of learning transfer and conceive-design-implement-operate, this study proposes a framework for course teaching reform of "Patient Safety" through a digital intelligence-empowered project-based teaching method. Moreover, teaching reform measures in the following three aspects are implemented, including the reform of teaching model through digital intelligence-empowered projects, the reform of teaching content, methods, and means by incorporating digital intelligence technology, and the reform of learning outcome evaluation by combining process and outcome assessments. Additionally, the study preliminarily explores the conditions for implementing the new teaching reforms and their effectiveness, providing a reference for the construction of similar courses.

Objective:To investigate the efficacy and safety of trastuzumab deruxtecan (T-DXd) in the treatment of metastatic breast cancer.Methods:A retrospective case series study was conducted. The clinical data of 38 breast cancer patients with metastasis in other parts who received T-DXd treatment in Xi'an International Medical Center Hospital from August 2021 to August 2024 were analyzed. The clinical efficacy and incidence of adverse reactions in patients were recorded, comparison of clinical efficacy in stratified patients based on clinical characteristics was performed, and the progression-free survival (PFS) was analyzed using Kaplan-Meier method.Results:All 38 patients were female, with a median age [ M ( Q1, Q3)] of 55 (42, 60) years; according to the guidelines of the American Society of Clinical Oncology/College of American Pathologists, 13 cases (34.2%) were positive for human epidermal growth factor receptor 2 (HER2) and 25 cases (65.8%) were low in HER2 expression; the Eastern Cooperative Oncology Group (ECOG) physical status scores of 23 cases (60.5%) were 0-2 points and 15 cases (39.5%) were 3-4 points; the median number of T-DXd treatment lines was 4 (2,16) lines. According to the Response Evaluation Criteria in Solid Tumors 1.1, the objective response rate (ORR) of T-DXd treatment was 34.2% (13/38), and the disease control rate (DCR) was 78.9% (30/38); the ORR of patients aged ≤ 50 years old was higher than that of patients aged >50 years old [56.3% (9/16) vs. 18.2% (4/22)], patients with HER2 positive was lower than that of patients with low HER2 expression [100.0 (13/13) vs. 68.0% (17/25)], patients with previous tyrosine kinase inhibitor (TKI) treatment was higher than that of patients without TKI treatment [100.0% (12/12) vs. 69.2% (18/26)], and the DCR of patients with T-DXd treatment for ≥ 4 cycles was higher than that of patients with T-DXd treatment for 1-3 cycles [100.0% (25/25) vs. 38.5% (5/13)], and the differences were statistically significant (all P < 0.05). Among the 38 patients, 19 (50.0%) stopped medication due to disease progression, 11 (28.9%) stopped medication due to economic reasons, 1 (0.8%) stopped medication due to grade 3 nausea and vomiting, and 1 (0.8%) stopped medication due to grade 2 interstitial lung disease (ILD), while the remaining 6 (15.8%) were undergoing T-DXd treatment. The median follow-up time was 9.5 (3.9, 17.8) months, and 16 cases (42.1%) progressed and died; the median PFS time was 5.9 months (95% CI: 3.1-8.7 months). Adverse reactions were mostly grade 1-2; common hematological adverse reactions included leukopenia [18 cases (47.3%)], neutropenia [16 cases (42.1%)], thrombocytopenia [11 cases (28.9%)], and anemia [15 cases (39.5%)]. Non-hematological adverse reactions included nausea [28 cases (73.7%)], vomiting [15 cases (39.5%)], decreased appetite [20 cases (52.6%)], fatigue [22 cases (57.9%)], alopecia [22 cases (57.5%)], elevated aspartate aminotransferase [20 cases (52.6%)], and elevated alanine aminotransferase [15 cases (39.5%)] were more common. Two cases developed interstitial lung disease (ILD), classified as grade 1 and grade 2, respectively. After discontinuation of medication and treatment with methylprednisolone, they returned to normal. Conclusions:T-DXd ≥ 2 line therapy has good efficacy and safety in the treatment of HER2 positive or low expression metastatic breast cancer. Bone marrow suppression and gastrointestinal adverse reactions are the most common, and the occurrence of ILD should be noted in the treatment.

Objective:To explore the clinicopathological characteristics and prognostic factors of hormone receptor-positive/human epidermal growth factor receptor 2-positive (HR +/HER2 +) breast cancer, and to construct a nomogram model for predicting the prognosis of patients. Methods:SEER*Stat 8.3.5 software was used to screen out the data of 11 664 HR +/HER2 + and 5,054 HR -/HER2 + breast cancer patients from 2010 to 2015 from the Surveillance, Epidemiology, and End Results (SEER) database. The clinicopathological data of the both groups were compared and the overall survival of the both groups was analyzed by using the Kaplan-Meier method and log-rank test was also performed; the factors influencing the overall survival in HR +/HER2 + patients with breast cancer were analyzed by using the Cox proportional hazards model. According to multivariate Cox regression analysis results, the median of the probability values of combined variables (linear predictive values) was calculated by using MedCalc software, with ≥ the median classified as high-risk group and < the median as low-risk group; the risk factor affinity diagrams were constructed by using R4.0.3 software. Based on the independent influencing factors of the overall survival in HR +/HER2 + breast cancer patients, a nomogram model to predict the 1-, 3-, 5-year overall survival of patients was established; the receiver operating characteristic (ROC) curve and calibration curve were plotted, and the predictive efficacy of the model was verified. Results:The differences in the proportions of HR +/HER2 + and HR -/HER2 + breast cancer patients with different age, race, histological grade, surgical method, whether receiving radiotherapy or chemotherapy, T stage, N stage, and M stage were statistically significant (all P < 0.05). The overall survival of HR +/HER2 + patients was better than that of HR -/HER2 + patients ( P < 0.001). Cox regression analysis showed that age, race, histological grade, surgical method, whether receiving radiotherapy or chemotherapy, first primary tumor or not, T stage, N stage, and M stage were independent influencing factors of overall survival in HR +/HER2 + patients (all P < 0.05). MedCalc software was used to obtain the median of the linear predictive values (0.394), with ≥ 0.394 classified as the high-risk group (5 838 cases) and < 0.394 as the low-risk group (5 826 cases). The risk factor affinity diagrams showed that all risk factors were more highly expressed in high-risk group compared with those in low-risk group; the overall survival of patients in high-risk group was poorer than that in low-risk group ( P < 0.001). The area under the ROC curve of a nomogram model for predicting the 1-, 3-, and 5-year overall survival rates was 0.900, 0.760, 0.760, respectively; and C index was 0.799, and the calibration curve was highly matched with the ideal curve. Conclusions:The prognosis of HR +/HER2 + patients is better than that of HR -/HER2 + patients. The constructed risk factor affinity diagrams and nomograms can well predict the prognosis of HR +/HER2 + breast cancer patients, which have a high clinical reference value.

Generally, small for gestational age(SGA) infants will catch up with growth after birth, but some SGAs fail to show enough catch-up growth, leading to physical growth backwardness, and the risk of metabolic diseases in adult offspring increases. The application of exogenous growth hormone replacement therapy can ensure and promote the occurrence of SGA catching up with growth. However, as growth hormone exerts therapeutic effects in related clinical diseases, clinical attention is gradually being paid to whether growth hormone may bring long-term risks. This article aims to review the efficacy and potential risks of growth hormone treatment for SGA.